Selexis, a Geneva, Switzerland-based life-sciences company focused on mammalian (suspension-adapted CHO-K1) cell line generation, has formed a new strategic agreement with Xencor, a Monrovia, California-based clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for autoimmune diseases, asthma, allergic diseases, and cancer. Under the agreement, Selexis will provide various cell line-related services that include personnel, laboratory equipment, laboratory space, and access to its SUREtechnology Platform. Selexis scientists will collaborate with Xencor scientists and project leaders on selected multi-specific antibody gene expression and cell line development programs.

This agreement builds on the business relationship that began between Xencor and Selexis with a service agreement in 2011. Since then, the relationship between the two companies has grown into a multi-cell line product license and, now, the strategic collaboration agreement.

Source: Selexis